Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Brain Neoplasms 33Glioblastoma 32Melanoma 21Glioma 19Neuroblastoma 7Carcinoma, Renal Cell 6Carcinoma, Non-Small-Cell Lung 6Astrocytoma 6Ependymoma 5Colorectal Neoplasms 5Central Nervous System Neoplasms 5Recurrence 4Ovarian Neoplasms 4Medulloblastoma 4Lymphoma 4Carcinoma, Hepatocellular 4Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Rhabdomyosarcoma 3Pancreatic Neoplasms 3Osteosarcoma 3Meningioma 3Lung Neoplasms 3Gliosarcoma 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xeroderma Pigmentosum × Nivolumab × CNS × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡